Floatz logo

Acalabrutinib

Leukemia

Inhye AhnSmall moleculePhase 1/2Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

View all 50

Same molecule, other indications

Acalabrutinib is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
75 / 100
View asset →
Grade 3a Follicular LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
follicular lymphomaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →